Hledat klinickou studii
46 Výsledků
Studie přijímající pacienty
= 
; Probíhající studie = 
; Ukončená studie = 
; Financováno členem konsorcia IRDiRC = 
; Člen ERN = 
Národní klinické studie
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
IMPACTT-PsAer-IgY: Prospektive, randomisierte, Placebo-kontrollierte, doppelblinde, multizentrische Phase III-Studie zur Einschätzung der klinischen Wirksamkeit und Sicherheit des polyclonalen Anti- Pseudomonas-Antikörpers IgY zur Vermeidung des Wiederauftretens einer Pseudomonas Aeruginosa-Infektion bei Patienten mit zystischer Fibrose
European Commission
DG Research - Directorate General for Research
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Portatori di mutazioni precliniche provenienti da famiglie con cardiomiopatia dilatativa e ACE-inibitori (PRECARDIA)
European Commission
DG Research - Directorate General for Research
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Ensayo multicéntrico y sin enmascaramiento de la seguridad y eficacia a largo plazo de Lamazym para el tratamiento de enfermos de alfamanosidosis (Fase II) (completado)
European Commission
DG Research - Directorate General for Research
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Estudio piloto multicéntrico, de brazo único, abierto para explorar la seguridad, tolerabilidad, la farmacocinética y la eficacia de administraciones múltiples intravenosas de NI-0501, un anticuerpo monoclonal anti-interferón gamma (Anti-IFNy), en pacientes pediátricos con linfohistiocitosis hemofagocítica primaria que se ha reactivado -ES (finalizado)
European Commission
DG Research - Directorate General for Research
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A phase IIb, open-label study to assess the efficacy, safety, pharmacodynamics and pharmacokinetics of multiple doses of BMN 045 (previously known as PRO045) in subjects with Duchenne muscular dystrophy - UK (Terminated)
European Commission
DG Research - Directorate General for Research
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
SONIA 2: An international, multicenter, randomized, evaluator-blinded, no-treatment controlled, parallel-group study to assess the efficacy and safety of once daily nitisinone in patients with alkaptonuria after 12 months of treatment, followed by an additional 36-month treatment period (phase III) - UK
European Commission
DG Research - Directorate General for Research
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
SONIA 2: An international, multicenter, randomized, evaluator-blinded, no-treatment controlled, parallel-group study to assess the efficacy and safety of once daily nitisinone in patients with alkaptonuria after 12 months of treatment, followed by an additional 36-month treatment period (phase III) - FR
European Commission
DG Research - Directorate General for Research
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
SONIA 2: An international, multicenter, randomized, evaluator-blinded, no-treatment controlled, parallel-group study to assess the efficacy and safety of once daily nitisinone in patients with alkaptonuria after 12 months of treatment, followed by an additional 36-month treatment period (phase III) - SK
European Commission
DG Research - Directorate General for Research
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A phase I/II, non randomized, multicenter, open-label study of G1XCGD (lentiviral vector transduced CD34+ cells) in patients with X-Linked Chronic Granulomatous Disease - UK
European Commission
DG Research - Directorate General for Research
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Estudio multicéntrico de seguimiento a largo plazo de pacientes con LHH que han recibido tratamiento con NI-0501, un anticuerpo monoclonal anti-interferón gamma (finalizado)
European Commission
DG Research - Directorate General for Research
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
MABSOT: A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanised Monoclonal Antibody that Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function - UK
European Commission
DG Research - Directorate General for Research
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A phase IIb, open-label study to assess the efficacy, safety, pharmacodynamics and pharmacokinetics of multiple doses of PRO045 in subjects with Duchenne muscular dystrophy - BE (Terminated)
European Commission
DG Research - Directorate General for Research
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Eine offene, einarmige, multizentrische Pilot-Studie zur Untersuchung der Sicherheit, Verträglichkeit, Pharmakokinetik und Wirksamkeit der mehrfach intravenöser Gabe von NI-0501, einem monoklonalen Anti-Interferon-Gamma (Anti-IFNy) Antikörper, bei pädiatrischen Patienten mit reaktivierter primären hämophagozytischen Lymphohistiozytose (Phase II)
European Commission
DG Research - Directorate General for Research
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Estudio de fase II, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos, adaptativo y secuencial en tres partes para evaluar la seguridad, tolerabilidad y eficacia de OPN305, un anticuerpo monoclonal humanizado que bloquea el receptor de tipo Toll 2, en pacientes con trasplante renal con riesgo elevado de retraso en la función del injerto (completado)
European Commission
DG Research - Directorate General for Research
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Eine Phase II-Studie des tumorspezifischen menschlichen Fusionsproteins monoklonalen Zytokin-Antikörpers F16IL2 in Kombination mit Paclitaxel versus Paclitaxel allein bei Patienten mit metastatischem Merkelzellkarzinom - DE -completed-
European Commission
DG Research - Directorate General for Research
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Studio pilota, in aperto, a singolo braccio, multicentrico, per esplorare la sicurezza, tollerabilità, farmacocinetica ed efficacia di somministrazioni intravenose multiple di NI-0501, un anticorpo monoclonale anti-interferone gamma (anti-IFNgamma), in pazienti pediatrici con Linfoistiocitosi emofagocitica primaria (HLH) riattivata
European Commission
DG Research - Directorate General for Research
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Neurosis : Etude de l'efficacité et de la tolérance du budésonide inhalé chez les nouveau-nés très grands prématurés, à risque de développer une dysplasie bronchopulmonaire - Phase III - FR
European Commission
DG Research - Directorate General for Research
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
IMPACTT-PsAer-IgY: Prospective randomized, placebo-controlled, double blind, multicenter study (phase III) to evaluate clinical efficacy and safety of avian polyclonal anti-Pseudomonas antibodies (IgY) in prevention of recurrence of Pseudomonas aeruginosa infection in cystic fibrosis patients - AT
European Commission
DG Research - Directorate General for Research
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Phase 2/3, Open-label, Single Arm, Multicentre Study to Assess Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Multiple Administrations of NI-0501, an Anti-interferon Gamma (Anti-IFNgamma) Monoclonal Antibody, in Paediatric Patients With Primary Haemophagocytic Lymphohistiocytosis - AT
European Commission
DG Research - Directorate General for Research
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Multicenter Study for the Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody (Phase II) - AT
European Commission
DG Research - Directorate General for Research
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
INTEREST study: Estudio comparativo de fase III de grupos paralelos, aleatorizado y doble ciego sobre la eficacia y seguridad de FP-1201-lyo (interferón beta-1A recombinante humano) y placebo en el tratamiento de pacientes con síndrome de dificultad respiratoria aguda grave o moderado - ES (finalizado)
European Commission
DG Research - Directorate General for Research
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
DietINT: A Randomized Phase II Study for Tertiary Prevention of Squamocellular Cancer of Head and Neck (SCCHN) With a Dietary Intervention - AT
European Commission
DG Research - Directorate General for Research
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
LENA-WP08: Orodispersible Minitablets of Enalapril in Children With Heart Failure Due to Dilated Cardiomyopathy (Phase II-III) - AT
European Commission
DG Research - Directorate General for Research
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Phase I/II G1XCGD.01 Sudie: Nicht randomisierte, multizentrische, offene Phase I/II-Gentherapiestudie mit g1xcgd (Lentiviral Vector Transduced cd34+ Cells) zur Behandlung der X-chromosomalen chronischen Granulomatose
European Commission
DG Research - Directorate General for Research
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Open-Label, Langzeit-Follow-up der Sicherheit und biochemischen Krankheitskontrolle von Infacort® bei Neugeborenen, Säuglingen und Kindern mit angeborener Nebennierenhyperplasie und Nebenniereninsuffizienz, die zuvor in die Infacort 003-Studie aufgenommen wurden
European Commission
DG Research - Directorate General for Research
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Studio di fase IIb randomizzato, in doppio cieco, a gruppi paralleli, placebo e controllo-attivo con estensione in doppio cieco per valutare l'efficacia e la sicurezza del vamorolone in ragazzi deambulanti con distrofia muscolare di duchenne (DMD)
European Commission
DG Research - Directorate General for Research
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Studio randomizzato, a controllo attivo, di fase 3 per valutare l'efficacia, la sicurezza e la tollerabilità della soluzione oftalmica di 0,08% di PHMB a confronto con lo 0,02% di PHMB + 0,1% di terapia a base di propamidina in soggetti affetti da cheratite da Acanthamoeba - IT
European Commission
DG Research - Directorate General for Research
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Projet "DeSScipher" - Déchiffrer le meilleur traitement pour la sclérodermie systémique - Etude observationnelle 2: Amélioration du dysfonctionnement des mains dû à l'arthrite dans la sclérodermie systémique- BE
European Commission
DG Research - Directorate General for Research
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
A Phase II study of the tumour-targeting human F16IL2 monoclonal antibody-cytokine fusion protein in combination with paclitaxel versus paclitaxel alone in patients with Merkel cell carcinoma - AT
European Commission
DG Research - Directorate General for Research
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Eine explorative klinische Studie von Patienten in der frühen Phase der Huntington-Krankheit zur Beurteilung der Pharmakokinetik, der pharmakodynamischen Messungen des Zieleingriffs und der Krankheitsmodulation sowie der akuten phänotypischen Effekte nach mehreren oralen Dosen von SEN0014196
European Commission
DG Research - Directorate General for Research
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Eine offene Phase-3-Studie von Infacort® bei Neugeborenen, Säuglingen und Kindern unter 6 Jahren mit Nebenniereninsuffizienz
European Commission
DG Research - Directorate General for Research
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Randomized controlled trial (RCT) to determine the efficacy and safety of azithromycin (AZN) maintenance therapy for 6 months in subjects with PCD - A double-blind, parallel group study - GB
European Commission
DG Research - Directorate General for Research
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
GANNET53: A Two-part, Multicentre, International Phase I and II Trial Assessing the Safety and Efficacy of the Hsp90 Inhibitor Ganetespib in Combination With Paclitaxel Weekly in Women With High-grade Serous, High-grade Endometrioid, or Undifferentiated, Platinum-resistant Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer - AT
European Commission
DG Research - Directorate General for Research
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
Randomisierte kontrollierte Studie (RCT) zur Bestimmung der Wirksamkeit und Sicherheit der Erhaltungstherapie mit Azithromycin (AZN) für 6 Monate bei Patienten mit PCD - Eine doppelblinde, parallele Gruppenstudie.
European Commission
DG Research - Directorate General for Research
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
HepaVac-101: Ensayo en fase I/II de IMA970A más CV8102 tras una única infusión prevacunal de ciclofosfamida en pacientes con carcinoma hepatocelular en estadio muy inicial, inicial o intermedio que han recibido tratamientos habituales de todo tipo (finalizado)
European Commission
DG Research - Directorate General for Research
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
HepaVac-101: A Phase I/II Trial of IMA970A Plus CV8102 Following a Single Pre-vaccination Infusion of Cyclophosphamide in Patients With Very Early, Early and Intermediate Stage of Hepatocellular Carcinoma After Any Standard Treatments - GB
European Commission
DG Research - Directorate General for Research
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
HepaVac-101: Essai de phase I / II portant sur IMA970A plus CV8102 après une perfusion unique de cyclophosphamide avant la vaccination chez des patients présentant un carcinome hépatocellulaire aux stades très précoce, précoce et intermédiaire après tout traitement standard - BE
European Commission
DG Research - Directorate General for Research
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
EUDARIO: essai de phase II multicentrique, ouverte, randomisée, à trois bras évaluant l'innocuité et l'efficacité de Ganetespib, un inhibiteur de HSP90, en association avec le Carboplatine, suivi d'un traitement d'entretien au Niraparib versus Ganetespib plus Carboplatin chez des patientes atteintes d'un cancer ovarien sensible au platine - BE
European Commission
DG Research - Directorate General for Research
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
HepaVac-101: Eine Phase-I/II-Studie mit IMA970A plus CV8102 nach einer einzigen Präimpf-Infusion von Cyclophosphamid bei Patienten mit einem sehr frühen, frühen und mittleren Stadium des hepatozellulären Karzinoms nach allen Standardbehandlungen
European Commission
DG Research - Directorate General for Research
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
rEECur: International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma-GB
European Commission
DG Research - Directorate General for Research
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
ENALONG: Follow-up Safety Trial in Children With Chronic Heart Failure Therapy Receiving Orodispersible Minitablets of Enalapril (Phase II-III) - AT
European Commission
DG Research - Directorate General for Research
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
LENA-WP09: Orodispersible Minitablets of Enalapril in Young Children With Heart Failure Due to Congenital Heart Disease (Phase II-III) - AT
European Commission
DG Research - Directorate General for Research
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
rEECur: essai international, randomisé, contrôlé de chimiothérapies en traitement du sarcome d'Ewing récidivant et réfractaire primaire - BE
European Commission
DG Research - Directorate General for Research
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
rEECur: Internationale randomisierte kontrollierte Studie zur Chemotherapie für die Behandlung von rezidivierenden und primären refraktären Ewing-Sarkomen
European Commission
DG Research - Directorate General for Research
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS
EUDARIO: essai de phase II multicentrique, ouverte, randomisée, à trois bras évaluant l'innocuité et l'efficacité de Ganetespib, un inhibiteur de HSP90, en association avec le Carboplatine, suivi d'un traitement d'entretien au Niraparib versus Ganetespib plus Carboplatin chez des patientes atteintes d'un cancer ovarien sensible au platine - FR
European Commission
DG Research - Directorate General for Research
BELGIE
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS